Back to News
Market Impact: 0.7

Bolt Projects Sees Nearly 8x Revenue Surge In Q1 2025, Losses Narrow Slightly

BSLKTRTNNDAQ
Healthcare & BiotechCorporate EarningsCorporate Guidance & OutlookProduct LaunchesPatents & Intellectual PropertyCompany FundamentalsTechnology & Innovation
Bolt Projects Sees Nearly 8x Revenue Surge In Q1 2025, Losses Narrow Slightly

Bolt Projects Holdings (BSLK) reported Q1 2025 revenue of $0.17 million, a substantial increase from $0.02 million year-over-year, driven by strategic partnerships and strong reorders, particularly from the Goddess Maintenance Company; however, the company continues to operate at a loss, reporting a net loss of $6.0 million, though slightly improved from $6.6 million in Q1 2024, due to increased R&D and marketing expenses. Bolt reaffirmed its full-year 2025 revenue guidance of at least $4.5 million and projected 2026 revenue of at least $9.0 million, while ending the quarter with $1.0 million in cash and completing a 20-to-1 reverse stock split.

Analysis

Bolt Projects Holdings (BSLK) reported significant top-line acceleration in Q1 2025, with revenue reaching $0.17 million, a substantial increase from $0.02 million in the prior-year quarter, primarily driven by strategic partnerships, notably with the Goddess Maintenance Company, and strong reorders for its biotech-based materials. Despite this revenue growth, the company continues to operate at a net loss, which was $6.0 million, or $3.00 per share, a slight improvement from the $6.6 million net loss in Q1 2024, attributed to increased operating expenses supporting R&D, marketing expansion, and operational scaling. Consequently, Bolt's adjusted EBITDA loss widened to $3.1 million from $2.5 million year-over-year. Commercial momentum is evidenced by the addition of two new customers and robust repeat orders across existing product lines, including Freaks of Nature SPF products and Haus Labs mascara, with management indicating that repeat demand is tracking at the high end of projections. The company is also heavily investing in R&D and intellectual property, delivering new biotech material xl-silk, enhancing claims for b-silk, and expanding its patent portfolio to 75 granted and 114 pending. Bolt ended Q1 2025 with a reduced cash position of $1.0 million, down from $3.5 million at the end of 2024, and completed a 20-to-1 reverse stock split on April 22, 2025, subsequent to issuing over 340,000 shares to Triton by March 31 under a stock purchase agreement. Management reaffirmed aggressive full-year revenue guidance of at least $4.5 million for 2025 (compared to $1.4 million in 2024) and at least $9.0 million for 2026, anticipating positive gross profit in both years and a long-term gross margin target of 60 percent, supported by a scalable supply chain and expected manufacturing cost reductions. The stock price has recently increased by 58.70% to $2.87, with its reported 1-year trading range of $220.3 to $2.89 likely reflecting pre-split and post-split values.